FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
Summary: In this March 31, 2026 announcement, FibroBiologics, Inc. (Nasdaq: FBLG) reports successful completion of cGMP manufacturing for its investigational fibroblast-derived therapy CYWC628. The product is advancing to support a first-in-human Phase 1/2 clinical trial evaluating safety and efficacy in patients with refractory diabetic foot ulcers (DFUs). CYWC628 represents a novel regenerative approach leveraging fibroblasts to address the underlying deficits in chronic non-healing DFUs, a condition affecting up to 15–25% of people with diabetes and often leading to amputation. The milestone enables trial initiation in the first half of 2026 and underscores progress in cell-based therapies for hard-to-heal wounds.
Key Highlights:
- Successful cGMP manufacturing of CYWC628 completed
- Prepares for Phase 1/2 trial in refractory DFU patients
- Fibroblast-based regenerative platform targeting chronic wound deficits
- Addresses high unmet need in diabetic foot ulcer management
Keywords: CYWC628, FibroBiologics, diabetic foot ulcer trial, fibroblast therapy